Market Closed -
Nasdaq
04:30:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
0.3996
USD
|
-1.16%
|
|
+2.46%
|
-44.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
77.86
|
336
|
95.83
|
11.03
|
10.96
|
7.415
|
-
|
-
|
Enterprise Value (EV)
1 |
77.86
|
336
|
95.83
|
11.03
|
10.96
|
7.415
|
7.415
|
7.415
|
P/E ratio
|
-3.11
x
|
-9.3
x
|
-1.82
x
|
-0.19
x
|
-0.23
x
|
-0.28
x
|
-0.3
x
|
-0.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,512
x
|
109
x
|
169
x
|
-26.4
x
|
3.51
x
|
742
x
|
0.83
x
|
-
|
EV / Revenue
|
2,512
x
|
109
x
|
169
x
|
-26.4
x
|
3.51
x
|
742
x
|
0.83
x
|
-
|
EV / EBITDA
|
-
|
-11,584,535
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,704
|
6,281
|
6,581
|
7,714
|
15,174
|
18,341
|
-
|
-
|
Reference price
2 |
21.02
|
53.50
|
14.56
|
1.430
|
0.7221
|
0.4043
|
0.4043
|
0.4043
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/31/22
|
3/30/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.031
|
3.069
|
0.567
|
-0.418
|
3.125
|
0.01
|
8.95
|
-
|
EBITDA
|
-
|
-29.01
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.58
|
-29.48
|
-51.92
|
-56.38
|
-35.29
|
-32.75
|
-26.59
|
-34.08
|
Operating Margin
|
-85,741.94%
|
-960.74%
|
-9,157.85%
|
13,486.84%
|
-1,129.22%
|
-327,530%
|
-297.07%
|
-
|
Earnings before Tax (EBT)
1 |
-24.87
|
-29.07
|
-51.59
|
-53.67
|
-40.29
|
-29.09
|
-24.5
|
-31.81
|
Net income
1 |
-24.87
|
-29.37
|
-51.59
|
-53.67
|
-40.29
|
-32.09
|
-24.85
|
-31.81
|
Net margin
|
-80,229.03%
|
-956.96%
|
-9,098.41%
|
12,839.71%
|
-1,289.25%
|
-320,945%
|
-277.63%
|
-
|
EPS
2 |
-6.750
|
-5.750
|
-8.000
|
-7.590
|
-3.160
|
-1.465
|
-1.365
|
-0.9900
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/31/22
|
3/30/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-0.001
|
0.02
|
-
|
-0.438
|
-
|
0.006
|
3.021
|
0.18
|
-0.082
|
0.02
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.03
|
-16.46
|
-14.81
|
-15.76
|
-9.347
|
-10.12
|
-
|
-
|
-10.15
|
-
|
-7.902
|
-7.553
|
-7.42
|
Operating Margin
|
1,403,300%
|
-82,300%
|
-
|
3,597.03%
|
-
|
-168,650%
|
-
|
-
|
12,374.39%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.95
|
-16.39
|
-14.98
|
-15.3
|
-7.005
|
-7.818
|
-
|
-
|
-16.53
|
-
|
-7.423
|
-7.065
|
-6.922
|
Net income
1 |
-13.95
|
-16.39
|
-15.04
|
-15.3
|
-7.005
|
-7.818
|
-
|
-
|
-16.53
|
-
|
-7.423
|
-7.065
|
-6.922
|
Net margin
|
1,395,300%
|
-81,945%
|
-
|
3,492.01%
|
-
|
-130,300%
|
-
|
-
|
20,156.1%
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.000
|
-2.500
|
-2.250
|
-2.250
|
-0.7300
|
-0.8100
|
-0.6900
|
-0.5700
|
-1.130
|
-0.3600
|
-0.4050
|
-0.3500
|
-0.3500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/11/22
|
8/11/22
|
11/9/22
|
3/30/23
|
5/15/23
|
8/14/23
|
11/14/23
|
4/1/24
|
5/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.02
|
0.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
2.82%
|
-6.7%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/31/22
|
3/30/23
|
4/1/24
|
-
|
-
|
-
|
Last Close Price
0.4043
USD Average target price
4
USD Spread / Average Target +889.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.66% | 7.42M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.57B | | +3.23% | 22.82B | | -10.44% | 18.19B | | -41.74% | 16.54B | | -13.31% | 16.5B | | +2.44% | 13.39B | | +27.89% | 11.1B |
Bio Therapeutic Drugs
|